Upstream Bio Earnings Estimate

UPB Stock   27.81  1.69  6.47%   
The next projected EPS of Upstream Bio is estimated to be -0.7 with future projections ranging from a low of -0.7425 to a high of -0.629275. Upstream Bio's most recent 12-month trailing earnings per share (EPS TTM) is at -6.4. Please be aware that the consensus of earnings estimates for Upstream Bio is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Covid
 
Interest Hikes
Upstream Bio is projected to generate -0.7 in earnings per share on the 31st of December 2025. Upstream Bio earnings estimates show analyst consensus about projected Upstream Bio EPS (Earning Per Share). It derives the highest and the lowest estimates based on Upstream Bio's historical volatility. Many public companies, such as Upstream Bio, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Upstream Bio's earnings estimates, investors can diagnose different trends across Upstream Bio's analyst sentiment over time as well as compare current estimates against different timeframes. As of February 11, 2026, Gross Profit is expected to decline to about 2.2 M. In addition to that, Pretax Profit Margin is expected to decline to -32Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Upstream Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation.
For information on how to trade Upstream Stock refer to our How to Trade Upstream Stock guide.

Upstream Bio Earnings Estimation Breakdown

The calculation of Upstream Bio's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Upstream Bio is estimated to be -0.7 with the future projection ranging from a low of -0.7425 to a high of -0.629275. Please be aware that this consensus of annual earnings estimates for Upstream Bio is based on EPS before non-recurring items and includes expenses related to employee stock options.
Last Reported EPS
-0.63
-0.74
Lowest
Expected EPS
-0.7
-0.63
Highest

Upstream Bio Earnings Projection Consensus

Suppose the current estimates of Upstream Bio's value are higher than the current market price of the Upstream Bio stock. In this case, investors may conclude that Upstream Bio is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Upstream Bio's stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyLast Reported EPSEstimated EPS for 31st of December 2025Current EPS (TTM)
877.78%
-0.63
-0.7
-6.4

Upstream Bio Earnings History

Earnings estimate consensus by Upstream Bio analysts from Wall Street is used by the market to judge Upstream Bio's stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we suggest analyzing not only Upstream Bio's upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods.

Upstream Bio Quarterly Gross Profit

652,000

As of February 11, 2026, Retained Earnings is expected to decline to about (180.3 M). In addition to that, Earnings Yield is expected to decline to -0.09 As of February 11, 2026, Common Stock Shares Outstanding is expected to decline to about 45.5 M.
Hype
Prediction
LowEstimatedHigh
23.1127.7232.33
Details
Intrinsic
Valuation
LowRealHigh
27.5832.1936.80
Details
4 Analysts
Consensus
LowTargetHigh
45.2749.7555.22
Details
Note that many institutional investors and large investment bankers can move markets due to the volume of Upstream assets they manage. They also follow analysts to some degree and often drive overall investor sentiments towards Upstream Bio. With so many stockholders watching consensus numbers, the difference between actual and projected earnings is one of the most critical factors driving Upstream Bio's stock price in the short term.

Upstream Bio Earnings per Share Projection vs Actual

Actual Earning per Share of Upstream Bio refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Upstream Bio predict the company's earnings will be in the future. The higher the earnings per share of Upstream Bio, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Upstream Bio Estimated Months Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Upstream Bio, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Upstream Bio should always be considered in relation to other companies to make a more educated investment decision.

Upstream Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact Upstream Bio's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2025-11-05
2025-09-30-0.77-0.630.1418 
2025-08-06
2025-06-30-0.61-0.74-0.1321 
2025-05-06
2025-03-31-0.48-0.51-0.03
2025-03-12
2024-12-31-0.5403-0.410.130324 
2024-11-07
2024-09-30-3.65-6.96-3.3190 
2024-08-28
2024-06-300-11.18-11.18

About Upstream Bio Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Upstream Bio earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Upstream Bio estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Upstream Bio fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for Next Year
Retained Earnings-171.7 M-180.3 M
Earnings Yield(0.09)(0.09)
Price Earnings Ratio(12.10)(12.70)
Price Earnings To Growth Ratio(0.29)(0.30)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Upstream Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Upstream Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Upstream Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Upstream Bio Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Upstream Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation.
For information on how to trade Upstream Stock refer to our How to Trade Upstream Stock guide.
You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Upstream Bio. If investors know Upstream will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Upstream Bio assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share
(6.40)
Revenue Per Share
0.054
Quarterly Revenue Growth
0.125
Return On Assets
(0.28)
Return On Equity
(0.41)
The market value of Upstream Bio is measured differently than its book value, which is the value of Upstream that is recorded on the company's balance sheet. Investors also form their own opinion of Upstream Bio's value that differs from its market value or its book value, called intrinsic value, which is Upstream Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Upstream Bio's market value can be influenced by many factors that don't directly affect Upstream Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Upstream Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Upstream Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Upstream Bio's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.